Bartlett, JB; Michael, A; Clarke, IA; Dredge, K; Nicholson, S; Kristeleit, H; Polychronis, A; Pandha, H; Muller, GW; Stirling, DI; et al. Bartlett, JB; Michael, A; Clarke, IA; Dredge, K; Nicholson, S; Kristeleit, H; Polychronis, A; Pandha, H; Muller, GW; Stirling, DI; Zeldis, J; Dalgleish, AG (2004) Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. BRITISH JOURNAL OF CANCER, 90 (5). 955 - 961 (7). ISSN 0007-0920 https://doi.org/10.1038/sj.bjc.6601579
SGUL Authors: Dalgleish, Angus George

Preview

["document_typename_application/pdf; charset=binary" not defined] Published Version Download (197kB) | Preview

Item Type:	Article
Additional Information:	PubMed ID: 14997189
Keywords:	Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Cytokines, Female, Fibroblast Growth Factor 2, Humans, Immunization, Male, Maximum Tolerated Dose, Melanoma, Middle Aged, Neoplasms, Safety, Skin Neoplasms, T-Lymphocytes, Thalidomide, Vascular Endothelial Growth Factor A, Science & Technology, Life Sciences & Biomedicine, Oncology, phase 1, CC-5013, thalidomide, immunomodulation, cytokines, T-cell activation, REFRACTORY MULTIPLE-MYELOMA, COLONY-STIMULATING FACTOR, LOW-DOSE THALIDOMIDE, CROHNS-DISEASE, CYTOKINE PRODUCTION, AGENT THALIDOMIDE, DRUG-RESISTANCE, DOUBLE-BLIND, THERAPY, TRIAL, phase 1, CC-5013, thalidomide, immunomodulation, cytokines, T-cell activation
SGUL Research Institute / Research Centre:	Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title:	BRITISH JOURNAL OF CANCER
ISSN:	0007-0920
Related URLs:	Author
Dates:	Date Event 8 March 2004 Published
Web of Science ID:	WOS:000220846800004
	Download EPMC Full text (PDF)
	Download EPMC Full text (HTML)
URI:	https://openaccess.sgul.ac.uk/id/eprint/52
Publisher's version:	https://doi.org/10.1038/sj.bjc.6601579

Actions (login required)

Edit Item